Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-03-27

Clinical Trial Update: Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy and safety of oral edaravone in amyotrophic lateral sclerosis has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Edaravone (Edaravone)

Snippet

Sponsor: Tanabe Pharma America, Inc. | Conditions: ALS | Phase 3 | Status: TERMINATED | Results posted: 2025-03-27